Rezul'taty ADVANCE 2007 goda:«nepravil'nye» otvety na nezadannye voprosy
- Authors: Aleksandrov A.A1
-
Affiliations:
- ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
- Issue: Vol 9, No 11 (2007)
- Pages: 76-80
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/92533
- ID: 92533
Cite item
Full Text
Abstract
В сентябре 2007 г. в Вене состо ялся очередной Европейский конгресс кардиологов. Одно из центральных событий конгресса было связано с первым публичным представлением результатов исследования ADVANCE (Action in Diabetes and VАscular disease – Pretrerax and DiamicroN MR Controlled Evaluation), посвященного предотвращению сердечно-сосудистых осложнений (ССО) сахарного диабета типа 2 (СД 2). Решение этой проблемы является одной из важнейших задач современной медицины.
Full Text
##article.viewOnOriginalSite##References
- Adler A, Stratton I.M, Neil H et al. Assotiation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9.
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.BMJ 1998; 317: 703–13.
- Hansson L, Zanchetti J.A, Carruthers S.G et al. HOT Study Group. Effects of intensive blood - pressure lowering and low - dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
- American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 2006; 29 (Suppl. 1): S4–S42.
- Lenfant C, Chobanian A.V, Jones D.W, Roccella E.J. Joint National Committee on the Prevention, Detection, Evalua tion, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003; 41: 1178–9.
- Guidelines on diabetes, pre - diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28 (1): 88–136.
- Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Associa tion. Circulation 2007; 115 (1): 114–26.
- Barkis G.L, Weir M.R, De Quattro V, Mc Mahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54 (4): 1283–9.
- Niskanen L, Hedner T, Hansson L et al. Reduced cardio vascular morbidity and mortality in hypertensive diabetic patients on first - line therapy with an ACE inhibitor com pared with a diuretic/beta - blocker - based treatment regi men: a subanalysis of the Captopril Prevention Project. Dia betes Care 2001; 24: 2091–6.
- Estacio R.O, Jeffers B.W, Hiatt W.R et al. The effect of nisoldipine as compared with enalapril on cardiovascular out comes in patients with non - insulin - dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52.
- Tatti P, Pahor M, Byington R.P et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
- Fressinaud P, Berrut G, Gallois H. Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice. Ann Cardiol Angeiol 1993; 42 (1): 51–9.
- Gosse P, Sheridan D.J, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
- Marre M, Fernandez M, Garcia-Puig J et al. Value of natrilix SR in hypertensive type 2 diabetic patients with microalbuminuria. J Hypertens 2002; 20 (suppl. 4): S338–42.
- PROGRESS Collaborative Groupe. (Writing committee: Mac Mahon S, Neal B, Tzouro C, Rodgers A, Woodward M, Cutler J, Anderson C and Chalmers with assistance of Ohku do T). Randomised trial of perindopril - based blood pressure lowering regimenamong 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
- London G.M, Asmar R.G, O'Rourke M.F et al., on behalf of the REASON Project Coordinators and ivestigators. Mechanism(s) of selective systolic blood pressure reduction after a low - dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9.
- Dahlöf B, Gosse P, Gueret P et al. Perindopril/inda pamide combination more effective then enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063–70.
- Mourad J.J, Hanon O, Deverre J.R et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low - dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 2003; 4: 94–5.
- Asia Pacific Cohort Studied Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004; 27: 2836–42.
- Stratton I.M, Adler A.L, Neil H.A et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observa tional study. BMJ 2000; 321: 405–12.
- Stettler C, Allemann S, Juni P et al. Glycaemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta - analysis of randomized trials. Am Heart J 2006; 152: 27–38.
- ADVANCE Cjllaborative Group. Effects of fixed combina tion of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; D01: 10.1016/S0140-6736(07)61303-8.
Supplementary files
